---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-056223"
form_type: "8-K"
ticker: "NUVL"
cik: "0001861560"
company_name: "Nuvalent, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T07:07:49.600738+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nuvalent reports Q1 net loss of $44.5M; cash $691.8M; pipeline milestones on track

## Summary
- Q1 2024 net loss of $44.5M; R&D expense $38.6M, G&A $14.0M.
- Cash, cash equivalents and marketable securities $691.8M as of March 31, 2024; runway into 2027.
- Updated data from ARROS-1 (ROS1) and ALKOVE-1 (ALK) trials expected at a medical meeting in H2 2024.
- Phase 1 trial for HER2 program (NVL-330) expected to initiate in 2024.
- Plans to outline front-line development strategy for ALK program in 2024.

## SEC filing metadata
- accession: 0000950170-24-056223
- form_type: 8-K
- ticker: NUVL
- cik: 0001861560
- company_name: Nuvalent, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1861560/000095017024056223/0000950170-24-056223-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1861560/000095017024056223/nuvl-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-056223
- JSON: https://secwatch.observer/filing/0000950170-24-056223.json
- Plain text: https://secwatch.observer/filing/0000950170-24-056223.txt

## Key facts
- Earnings Releases
  Nuvalent, Inc. reported first quarter 2024 results: net income Net loss was $44.5 million for the first quarter of 2024..
  - Period: first quarter 2024
  - Net income: Net loss was $44.5 million for the first quarter of 2024.
  - Result: reported results
  source text: Net loss was $44.5 million for the first quarter of 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1861560/000095017024056223/0000950170-24-056223-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.